Tapan Mahendra Kadia

Research output

Research output per year 1999 2017 2019 2020 2021 2022 2023 2024

• 355 Article
• 57 Letter
• 30 Review article
• 5 Comment/debate
• 4 More
  • 2 Chapter
  • 2 Short survey

Research output per year

Research output per year

Search results

• 2022

  A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

  Short, N. J., Borthakur, G., Pemmaraju, N., Dinardo, C. D., Kadia, T. M., Jabbour, E., Konopleva, M., Macaron, W., Ning, J., Ma, J., Pierce, S., Alvarado, Y., Sasaki, K., Takahashi, K., Estrov, Z., Masarova, L., Issa, G. C., Montalban-Bravo, G., Andreeff, M., Burger, J. A., & 6 othersMiller, D., Alexander, L., Naing, A., Garcia-Manero, G., Ravandi, F. & Daver, N., 2022, In: Leukemia and Lymphoma. 63, 9, p. 2161-2170 10 p.

  Research output: Contribution to journal › Article › peer-review

  • venetoclax 100%
  • Azacitidine 83%
  • Gemtuzumab 81%
  • avelumab 65%
  • Acute Myeloid Leukemia 60%
  12 Scopus citations

• A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations

  Desikan, S. P., Ravandi, F., Pemmaraju, N., Konopleva, M., Loghavi, S., Jabbour, E. J., Daver, N., Jain, N., Chien, K. S., Maiti, A., Montalban-Bravo, G., Kadia, T. M., MacAron, W., Delumpa, R., Kwari, M., Borthakur, G. & Short, N. J., Sep 1 2022, In: Acta haematologica. 145, 5, p. 529-536 8 p.

  Research output: Contribution to journal › Article › peer-review

  • venetoclax 100%
  • trametinib 98%
  • Azacitidine 83%
  • Acute Myeloid Leukemia 60%
  • Mutation 35%
  14 Scopus citations

• Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study

  Bazinet, A., Darbaniyan, F., Jabbour, E., Montalban-Bravo, G., Ohanian, M., Chien, K., Kadia, T., Takahashi, K., Masarova, L., Short, N., Alvarado, Y., Yilmaz, M., Ravandi, F., Andreeff, M., Kanagal-Shamanna, R., Ganan-Gomez, I., Colla, S., Qiao, W., Huang, X., McCue, D., & 3 othersMirabella, B., Kantarjian, H. & Garcia-Manero, G., Oct 2022, In: The Lancet Haematology. 9, 10, p. e756-e765

  Research output: Contribution to journal › Article › peer-review

  • venetoclax 100%
  • Leukemia, Myelomonocytic, Chronic 91%
  • Azacitidine 83%
  • Myelodysplastic Syndromes 71%
  • Maximum Tolerated Dose 21%
  38 Scopus citations

• Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10⁻⁴ and higher

  Jabbour, E. J., Short, N. J., Jain, N., Jammal, N., Jorgensen, J., Wang, S., Wang, X., Ohanian, M., Alvarado, Y., Kadia, T., Sasaki, K., Garris, R., Garcia-Manero, G., Ravandi, F. & Kantarjian, H. M., Sep 2022, In: American journal of hematology. 97, 9, p. 1135-1141 7 p.

  Research output: Contribution to journal › Article › peer-review

  • blinatumomab 100%
  • Cell Lineage 60%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 56%
  • B-Lymphocytes 44%
  • Confidence Intervals 22%
  12 Scopus citations

• Changing Paradigms in the Treatment of Acute Myeloid Leukemia in Older Patients

  Bazinet, A. & Kadia, T. M., Jan 2022, In: Clinical Advances in Hematology and Oncology. 20, 1, p. 37-46 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Acute Myeloid Leukemia 100%
  • venetoclax 27%
  • Recurrence 20%
  • Frailty 19%
  • Nucleosides 18%
  8 Scopus citations

• Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

  Pemmaraju, N., Wilson, N. R., Garcia-Manero, G., Sasaki, K., Khoury, J. D., Jain, N., Borthakur, G., Ravandi, F., Daver, N., Kadia, T., DiNardo, C., Jabbour, E., Pierce, S., Qazilbash, M., Konopleva, M. & Kantarjian, H., May 24 2022, In: Blood Advances. 6, 10, p. 3027-3035 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Vincristine 100%
  • Cyclophosphamide 86%
  • Doxorubicin 85%
  • Dexamethasone 84%
  • Dendritic Cells 82%
  18 Scopus citations

• Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

  Abbas, H. A., Ayoub, E., Sun, H., Kanagal-Shamanna, R., Short, N. J., Issa, G., Yilmaz, M., Pierce, S., Rivera, D., Cham, B., Wing, S., Li, Z., Hammond, D., Jabbour, E., Borthakur, G., Garcia-Manero, G., Andreeff, M., Daver, N., Kadia, T., Konopleva, M., & 2 othersDiNardo, C. & Ravandi, F., 2022, In: Leukemia and Lymphoma. 63, 13, p. 3105-3116 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Chromosomes, Human, Pair 7 80%
  • Acute Myeloid Leukemia 60%
  • Therapeutics 10%
  • Mutation 10%
  4 Scopus citations

• Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors

  Mukherjee, A., Milton, D. R., Jabbour, E. J., Gulbis, A. M., Kadia, T., Jain, N., Ledesma, C., Burger, J., Ferrajoli, A., Wierda, W., Medeiros, L. J., Kantarjian, H., Champlin, R. & Khouri, I. F., 2022, In: Leukemia and Lymphoma. 63, 4, p. 885-893 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Allogeneic Cells 100%
  • Stem Cell Transplantation 97%
  • Graft vs Host Disease 73%
  • B-Lymphocytes 71%
  • idelalisib 38%
  1 Scopus citations

• Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients with Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies

  Rausch, C. R., DiPippo, A. J., Jiang, Y., DiNardo, C. D., Kadia, T., Maiti, A., Montalban-Bravo, G., Ravandi, F. & Kontoyiannis, D. P., Nov 1 2022, In: Clinical Infectious Diseases. 75, 9, p. 1503-1510 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Triazoles 100%
  • Invasive Fungal Infections 95%
  • Acute Myeloid Leukemia 70%
  • Fungi 66%
  • Remission Induction 60%
  14 Scopus citations

• Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment

  Lachowiez, C. A., Reville, P. K., Kantarjian, H., Jabbour, E., Borthakur, G., Daver, N., Issa, G., Furudate, K., Tanaka, T., Pierce, S., Tang, G., Patel, K. P., Medeiros, J., Abbas, H. A., Haddad, F., Hammond, D., Short, N. J., Maiti, A., Yilmaz, M., Sasaki, K., & 8 othersTakahashi, K., Pemmaraju, N., Konopleva, M., Garcia-Manero, G., Ravandi, F., Kadia, T. M., Loghavi, S. & DiNardo, C. D., Nov 2022, In: American journal of hematology. 97, 11, p. 1443-1452 10 p.

  Research output: Contribution to journal › Article › peer-review

  • venetoclax 100%
  • Acute Myeloid Leukemia 60%
  • Mutation 35%
  • Survival 10%
  • Therapeutics 10%
  10 Scopus citations

• Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy

  Tashakori, M., Wang, W., Kadia, T. M., Daver, N. G., Montalban-Bravo, G., Loghavi, S., Wang, S. A., Medeiros, L. J., Ravandi, F. & Khoury, J. D., Jul 2022, In: Leukemia Research. 118, 106860.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia 100%
  • Therapeutics 20%
  • Mutation 12%
  • Monosomy 9%
  • Missense Mutation 7%
  2 Scopus citations

• Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia

  Venugopal, S., DiNardo, C. D., Loghavi, S., Qiao, W., Ravandi, F., Konopleva, M., Kadia, T., Bhalla, K., Jabbour, E., Issa, G. C., Macaron, W., Daver, N., Borthakur, G., Montalban-Bravo, G., Yilmaz, M., Patel, K. P., Kanagal-Shamanna, R., Chien, K., Maiti, A., Kantarjian, H., & 1 othersShort, N. J., Dec 2022, In: American journal of hematology. 97, 12, p. 1560-1567 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Acute Myeloid Leukemia 100%
  • venetoclax 95%
  • Mutation 58%
  • Survival 41%
  • Drug Therapy 35%
  8 Scopus citations

• Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

  Fiskus, W., Boettcher, S., Daver, N., Mill, C. P., Sasaki, K., Birdwell, C. E., Davis, J. A., Takahashi, K., Kadia, T. M., DiNardo, C. D., Jin, Q., Qi, Y., Su, X., McGeehan, G. M., Khoury, J. D., Ebert, B. L. & Bhalla, K. N., Jan 2022, In: Blood cancer journal. 12, 1, 5.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Mutation 100%
  • venetoclax 94%
  • 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine 53%
  • Cell Line 35%
  • Clustered Regularly Interspaced Short Palindromic Repeats 34%
  47 Scopus citations

• Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2

  Mill, C. P., Fiskus, W., DiNardo, C. D., Birdwell, C., Davis, J. A., Kadia, T. M., Takahashi, K., Short, N., Daver, N., Ohanian, M., Borthakur, G., Kornblau, S. M., Green, M. R., Qi, Y., Su, X., Khoury, J. D. & Bhalla, K. N., Feb 10 2022, In: Blood. 139, 6, p. 907-921 15 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Venetoclax 100%
  • Homoharringtonine 52%
  • Protein Biosynthesis 50%
  • Acute Myeloid Leukemia 44%
  • Mutation 39%
  29 Scopus citations

• Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

  Venugopal, S., Takahashi, K., Daver, N., Maiti, A., Borthakur, G., Loghavi, S., Short, N. J., Ohanian, M., Masarova, L., Issa, G., Wang, X., Carlos, B. R., Yilmaz, M., Kadia, T., Andreeff, M., Ravandi, F., Konopleva, M., Kantarjian, H. M. & DiNardo, C. D., Jan 2022, In: Blood cancer journal. 12, 1, 10.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • AG-221 100%
  • Azacitidine 68%
  • Acute Myeloid Leukemia 49%
  • venetoclax 32%
  • Drug Therapy 30%
  45 Scopus citations

• High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance

  Yang, H., Garcia-Manero, G., Sasaki, K., Montalban-Bravo, G., Tang, Z., Wei, Y., Kadia, T., Chien, K., Rush, D., Nguyen, H., Kalia, A., Nimmakayalu, M., Bueso-Ramos, C., Kantarjian, H., Medeiros, L. J., Luthra, R. & Kanagal-Shamanna, R., Sep 2022, In: Leukemia. 36, 9, p. 2306-2316 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Chromosome Mapping 100%
  • Myelodysplastic Syndromes 91%
  • Chromosome Banding 75%
  • Cytogenetics 48%
  • Standard of Care 31%
  37 Scopus citations

• High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

  Short, N. J., Kantarjian, H., Ravandi, F., Konopleva, M., Jain, N., Kanagal-Shamanna, R., Patel, K. P., MacAron, W., Kadia, T. M., Wang, S., Jorgensen, J. L., Khoury, J. D., Yilmaz, M., Kebriaei, P., Takahashi, K., Garcia-Manero, G., Daver, N., Post, S. M., Huang, X., Kornblau, S. M., & 5 othersPelletier, S., Flores, W., Matthews, J., Garris, R. & Jabbour, E., Jul 12 2022, In: Blood Advances. 6, 13, p. 4006-4014 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 100%
  • High-Throughput Nucleotide Sequencing 97%
  • Recurrence 58%
  • Flow Cytometry 29%
  • Survival 13%
  32 Scopus citations

• Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial

  Jabbour, E., Short, N. J., Jain, N., Thompson, P. A., Kadia, T. M., Ferrajoli, A., Huang, X., Yilmaz, M., Alvarado, Y., Patel, K. P., Garcia-Manero, G., Macaron, W., Garris, R., Konopleva, M., Ravandi, F. & Kantarjian, H., Dec 2022, In: The Lancet Haematology. 9, 12, p. e878-e885

  Research output: Contribution to journal › Article › peer-review

  • blinatumomab 100%
  • B-Cell Leukemia 80%
  • Philadelphia Chromosome 73%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 56%
  • Drug Therapy 11%
  25 Scopus citations

• Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

  Yilmaz, M., Kantarjian, H., Short, N. J., Reville, P., Konopleva, M., Kadia, T., DiNardo, C., Borthakur, G., Pemmaraju, N., Maiti, A., Jabbour, E., Jain, N., Issa, G., Takahashi, K., Sasaki, K., Ohanian, M., Pierce, S., Tang, G., Loghavi, S., Patel, K., & 5 othersWang, S. A., Garcia-Manero, G., Andreeff, M., Ravandi, F. & Daver, N., May 2022, In: Blood cancer journal. 12, 5, 77.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Acute Myeloid Leukemia 60%
  • Drug Therapy 22%
  • Clinical Trials 16%
  • Survival 13%
  32 Scopus citations

• Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

  Short, N. J., Venugopal, S., Qiao, W., Kadia, T. M., Ravandi, F., Macaron, W., Dinardo, C. D., Daver, N., Konopleva, M., Borthakur, G., Shpall, E. J., Popat, U., Champlin, R. E., Mehta, R., Al-Atrash, G., Oran, B., Jabbour, E., Garcia-Manero, G., Issa, G. C., Montalban-Bravo, G., & 3 othersYilmaz, M., Maiti, A. & Kantarjian, H., Dec 2022, In: Journal of Hematology and Oncology. 15, 1, 12.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Acute Myeloid Leukemia 30%
  • Karyotype 24%
  • Hematopoietic Stem Cell Transplantation 16%
  • Leukemia, Myelomonocytic, Chronic 11%
  14 Scopus citations

• Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes

  Rivera, D., Kim, K., Kanagal-Shamanna, R., Borthakur, G., Montalban-Bravo, G., Daver, N., Dinardo, C., Short, N. J., Yilmaz, M., Pemmaraju, N., Takahashi, K., Jabbour, E. J., Pierce, S., Konopleva, M., Bhalla, K., Garcia-Manero, G., Ravandi, F., Kantarjian, H. & Kadia, T. M., Dec 2022, In: American journal of hematology. 97, 12, p. 1599-1606 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Acute Myeloid Leukemia 100%
  • Mutation 39%
  • Karyotype 35%
  • venetoclax 27%
  • Drug Therapy 20%
  6 Scopus citations

• Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

  Reville, P. K., Sasaki, K., Kantarjian, H. M., Daver, N. G., Yilmaz, M., Dinardo, C. D., Short, N. J., Borthakur, G., Pemmaraju, N., Mehta, R. S., Pierce, S., Konoplev, S. N., Khoury, J. D., Garcia-Manero, G., Konopleva, M. Y., Jabbour, E., Ravandi, F. & Kadia, T. M., Mar 1 2022, In: American journal of hematology. 97, 3, p. 329-337 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • fms-Like Tyrosine Kinase 3 100%
  • Acute Myeloid Leukemia 56%
  • Protein-Tyrosine Kinases 54%
  • Mutation 27%
  • Allogeneic Cells 17%
  14 Scopus citations

• Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

  Sperling, A. S., Guerra, V. A., Kennedy, J. A., Yan, Y., Hsu, J. I., Wang, F., Nguyen, A. T., Miller, P. G., McConkey, M. E., Quevedo Barrios, V. A., Furudate, K., Zhang, L., Kanagal-Shamanna, R., Zhang, J., Little, L., Gumbs, C., Daver, N., DiNardo, C. D., Kadia, T., Ravandi, F., & 5 othersKantarjian, H., Garcia-Manero, G., Futreal, P. A., Ebert, B. L. & Takahashi, K., Oct 20 2022, In: Blood. 140, 16, p. 1753-1763 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lenalidomide 100%
  • Second Primary Neoplasms 63%
  • Hematopoietic Stem Cells 54%
  • Mutation 46%
  • Hematopoiesis 22%
  59 Scopus citations

• Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis

  Berkman, A. M., Andersen, C. R., Cuglievan, B., McCall, D. C., Lupo, P. J., Parsons, S. K., DiNardo, C. D., Short, N. J., Jain, N., Kadia, T. M., Livingston, J. A. & Roth, M. E., Jun 2022, In: Cancer Epidemiology Biomarkers and Prevention. 31, 6, p. 1176-1184 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Survivors 100%
  • Leukemia 93%
  • Young Adult 92%
  • Epidemiology 89%
  • Survival 42%
  5 Scopus citations

• MDS-406 Prognostic Implication of the Molecular Profiles of Patients With Hypocellular Myelodysplastic Syndrome

  Kim, K., Ong, F., Montalban-Bravo, G., Shamanna, R. K., Kadia, T., Jabbour, E., Alvarado, Y., Sasaki, K., Dong, X. Q., Pierce, S., Bueso-Ramos, C., Kantarjian, H., Kelly, C. & Garcia-Manero, G., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S310

  Research output: Contribution to journal › Article › peer-review

  • Myelodysplastic Syndromes 100%
  • Mutation 49%
  • Survival 17%
  • Mutation Rate 6%
  • Cytogenetics 6%

• MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes

  Chien, K., Kim, K., Li, Z., Shamanna, R. K., Ong, F., Bravo, G. M., Kadia, T., Jabbour, E., Pemmaraju, N., Hammond, D., Short, N., Ravandi, F., Alvarado, Y., Pierce, S., Dong, X. Q., Kantarjian, H. & Garcia-Manero, G., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S311

  Research output: Contribution to journal › Article › peer-review

  • Myelodysplastic Syndromes 100%
  • Proxy 30%
  • Survival 27%
  • Bone Marrow 21%
  • Mutation 16%

• MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes

  Kim, K., Ong, F., Li, Z., Shamanna, R. K., Bravo, G. M., Kadia, T., Jabbour, E., Pemmaraju, N., Hammond, D., Short, N., Ravandi, F., Alvarado, Y., Pierce, S., Dong, X. Q., Kantarjian, H., Garcia-Manero, G. & Chien, K., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S313-S314

  Research output: Contribution to journal › Article › peer-review

  • Myelodysplastic Syndromes 100%
  • Acute Myeloid Leukemia 84%
  • Survival 20%
  • Cytogenetics 14%
  • Therapeutics 14%

• MDS-508 Contemporary Evaluation of a Cohort of Patients With Clonal Hematopoiesis (CH): A Single Institution Experience

  Ong, F., Kim, K., Shamanna, R. K., DiNardo, C., Takahashi, K., Kadia, T., Jabbour, E., Short, N. J., Hammond, D., Pemmaraju, N., Pierce, S. A., Bravo, G. M., Kantarjian, H., Garcia-Manero, G. & Chien, K. S., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S319

  Research output: Contribution to journal › Article › peer-review

  • Myelodysplastic Syndromes 100%
  • Hematopoiesis 96%
  • Survival 39%
  • GATA2 Deficiency 36%
  • Neoplasms 28%

• MDS-520 A Phase I/II Study of Venetoclax in Combination With ASTX727 (Decitabine/Cedazuridine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

  Venugopal, S., Kantarjian, H., Maiti, A., Short, N. J., Montalban-Bravo, G., Alvarado, Y., Chien, K., Kanagal-Shamanna, R., Pemmaraju, N., Daver, N., Kadia, T., Borthakur, G., Jabbour, E. & Garcia-Manero, G., Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S321

  Research output: Contribution to journal › Article › peer-review

  • cedazuridine 100%
  • venetoclax 61%
  • Leukemia, Myelomonocytic, Chronic 56%
  • Decitabine 50%
  • Myelodysplastic Syndromes 43%

• Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

  Kadia, T. M., Reville, P. K., Wang, X., Rausch, C. R., Borthakur, G., Pemmaraju, N., Daver, N. G., Dinardo, C. D., Sasaki, K., Issa, G. C., Ohanian, M., Montalban-Bravo, G., Short, N. J., Jain, N., Ferrajoli, A., Bhalla, K. N., Jabbour, E., Takahashi, K., Malla, R., Quagliato, K., & 7 othersKanagal-Shamanna, R., Popat, U. R., Andreeff, M., Garcia-Manero, G., Konopleva, M. Y., Ravandi, F. & Kantarjian, H. M., Jun 1 2022, In: Journal of Clinical Oncology. 374, JCO.21.02823.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Cladribine 91%
  • Azacitidine 83%
  • Cytarabine 71%
  • Acute Myeloid Leukemia 60%
  38 Scopus citations

• Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study

  Sheshadri, A., Goizueta, A. A., Shannon, V. R., London, D., Garcia-Manero, G., Kantarjian, H. M., Ravandi-Kashani, F., Kadia, T. M., Konopleva, M. Y., DiNardo, C. D., Pierce, S., Zarifa, A., Albittar, A. A., Zhong, L. L., Akhmedzhanov, F. O., Arain, M. H., Alfayez, M., Alotaibi, A., Altan, M., Naing, A., & 9 othersMendoza, T. R., Godoy, M. C. B., Shroff, G., Kim, S. T., Faiz, S. A., Kontoyiannis, D. P., Khawaja, F., Jennings, K. & Daver, N. G., Jul 15 2022, In: Cancer. 128, 14, p. 2736-2745 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Acute Myeloid Leukemia 100%
  • Pneumonia 84%
  • Cohort Studies 71%
  • Retrospective Studies 70%
  • Therapeutics 17%
  8 Scopus citations

• Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy

  Sasaki, K., Kadia, T., Begna, K., DiNardo, C. D., Borthakur, G., Short, N. J., Jain, N., Daver, N., Jabbour, E., Garcia-Manero, G., Bravo, G. M., Masarova, L., Pierce, S., Konopleva, M., Ravandi, F., Tefferi, A. & Kantarjian, H., Jan 1 2022, In: American journal of hematology. 97, 1, p. 68-78 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Acute Myeloid Leukemia 100%
  • Drug Therapy 61%
  • Mortality 52%
  • Chromosome Aberrations 28%
  • Core Binding Factors 23%
  22 Scopus citations

• Prediction of survival with intensive chemotherapy in acute myeloid leukemia

  Sasaki, K., Ravandi, F., Kadia, T., DiNardo, C., Borthakur, G., Short, N., Jain, N., Daver, N., Jabbour, E., Garcia-Manero, G., Khoury, J., Konoplev, S., Loghavi, S., Patel, K., Montalban-Bravo, G., Masarova, L., Konopleva, M. & Kantarjian, H., Jul 2022, In: American journal of hematology. 97, 7, p. 865-876 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Acute Myeloid Leukemia 100%
  • Drug Therapy 61%
  • Survival 58%
  • Mutation 35%
  • Fever of Unknown Origin 28%
  12 Scopus citations

• Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients

  Borthakur, G., Ravandi, F., Patel, K., Wang, X., Kadia, T., DiNardo, C., Garcia-Manero, G., Pemmaraju, N., Jabbour, E. J., Takahashi, K., Ohanian, M., Daver, N., Alvarado, Y., Brandt, M., Pierce, S. & Kantarjian, H., Nov 2022, In: American journal of hematology. 97, 11, p. 1427-1434 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Gemtuzumab 100%
  • Core Binding Factors 96%
  • Idarubicin 90%
  • fludarabine 79%
  • Cytarabine 70%
  9 Scopus citations

• TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

  Tashakori, M., Kadia, T., Loghavi, S., Daver, N., Kanagal-Shamanna, R., Pierce, S., Sui, D., Wei, P., Khodakarami, F., Tang, Z., Routbort, M., Bivins, C. A., Jabbour, E. J., Medeiros, L. J., Bhalla, K., Kantarjian, H. M., Ravandi, F. & Khoury, J. D., Jul 7 2022, In: Blood. 140, 1, p. 58-72 15 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Acute Myeloid Leukemia 100%
  • Mutation 88%
  • Protein 43%
  • Proteins 38%
  • Immunohistochemistry 16%
  44 Scopus citations

• TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

  Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia-Manero, G., Craddock, C., Sallman, D. A. & Kantarjian, H. M., Nov 1 2022, In: Cancer discovery. 12, 11, p. 2516-2529 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • GATA2 Deficiency 100%
  • Direction compound 52%
  • venetoclax 19%
  • Induction Chemotherapy 14%
  • Tumor Microenvironment 12%
  41 Scopus citations

• Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors

  Haddad, F. G., Sasaki, K., Issa, G. C., Garcia-Manero, G., Ravandi, F., Kadia, T., Cortes, J., Konopleva, M., Pemmaraju, N., Alvarado, Y., Yilmaz, M., Borthakur, G., DiNardo, C., Jain, N., Daver, N., Short, N. J., Jabbour, E. & Kantarjian, H., Jul 2022, In: American journal of hematology. 97, 7, p. 856-864 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive 100%
  • Protein-Tyrosine Kinases 86%
  • Philadelphia Chromosome 36%
  • Therapeutics 15%
  • Multivariate Analysis 13%
  34 Scopus citations

• Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials

  Kim, K., Konopleva, M., DiNardo, C. D., Borthakur, G., Loghavi, S., Tang, G., Daver, N., Pemmaraju, N., Jabbour, E., Rausch, C. R., Yilmaz, M., Sasaki, K., Short, N. J., Jain, N., Brandt, M., Pierce, S., Garcia-Manero, G., Ravandi, F., Kantarjian, H. & Kadia, T. M., Jul 2022, In: American journal of hematology. 97, 7, p. 885-894 10 p.

  Research output: Contribution to journal › Article › peer-review

  • Acute Myeloid Leukemia 100%
  • Clinical Trials 68%
  • Hydroxyurea 63%
  • Cytarabine 59%
  • Survival 29%
  4 Scopus citations

• Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline ‘chemotherapy-free’ therapy

  Ramos Perez, J. M., Patel, K. P., Loghavi, S., Garcia-Manero, G., Borthakur, G., Jabbour, E., Wierda, W., Pierce, S., Brandt, M., Kornblau, S., Kadia, T., Daver, N., DiNardo, C. D., Jain, N., Yilmaz, M., Short, N., Verstovsek, S., Ferrajoli, A., Andreeff, M., Konopleva, M., & 4 othersRivera, D., McCue, D., Kantarjian, H. M. & Ravandi, F., 2022, In: Leukemia and Lymphoma. 63, 3, p. 672-675 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Acute Promyelocytic Leukemia 100%
  • Physiologic Monitoring 84%
  • Drug Therapy 47%
  • Recurrence 22%
  • Arsenic Trioxide 17%
  1 Scopus citations

• Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia

  DiNardo, C. D., Lachowiez, C. A., Takahashi, K., Loghavi, S., Kadia, T., Daver, N., Xiao, L., Adeoti, M., Short, N. J., Sasaki, K., Wang, S. A., Borthakur, G., Issa, G., Maiti, A., Alvarado, Y., Pemmaraju, N., Bravo, G. M., Masarova, L., Yilmaz, M., Jain, N., & 7 othersAndreeff, M., Garcia-Manero, G., Kornblau, S., Ravandi, F., Jabbour, E., Konopleva, M. Y. & Kantarjian, H. M., Aug 2022, In: American journal of hematology. 97, 8, p. 1035-1043 9 p.

  Research output: Contribution to journal › Article › peer-review

  • venetoclax 100%
  • Acute Myeloid Leukemia 60%
  • Induction Chemotherapy 37%
  • Progression-Free Survival 28%
  • Survival 23%
  27 Scopus citations

• Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study

  Lachowiez, C. A., Reville, P. K., Kantarjian, H., Jabbour, E., Borthakur, G., Daver, N., Loghavi, S., Furudate, K., Xiao, L., Pierce, S., Short, N. J., Maiti, A., Yilmaz, M., Sasaki, K., Takahashi, K., Konopleva, M., Pemmaraju, N., Popat, U., Shpall, E., Garcia-Manero, G., & 3 othersRavandi, F., DiNardo, C. D. & Kadia, T. M., May 2022, In: The Lancet Haematology. 9, 5, p. e350-e360

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Induction Chemotherapy 75%
  • Propensity Score 67%
  • Acute Myeloid Leukemia 60%
  • Cohort Studies 42%
  28 Scopus citations
• 2021

  Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

  Montalban-Bravo, G., Hammond, D., DiNardo, C. D., Konopleva, M., Borthakur, G., Short, N. J., Ramos-Perez, J., Guerra, V., Kanagal-Shamanna, R., Naqvi, K., Sasaki, K., Jabbour, E., Pemmaraju, N., Kadia, T. M., Ravandi, F., Daver, N., Estrov, Z., Pierce, S., Kantarjian, H. & Garcia-Manero, G., May 2021, In: Leukemia. 35, 5, p. 1494-1499 6 p.

  Research output: Contribution to journal › Article › peer-review
  14 Scopus citations

• A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia

  Saxena, K., Herbrich, S. M., Pemmaraju, N., Kadia, T. M., DiNardo, C. D., Borthakur, G., Pierce, S. A., Jabbour, E., Wang, S. A., Bueso-Ramos, C., Loghavi, S., Tang, G., Cheung, C. M., Alexander, L., Kornblau, S., Andreeff, M., Garcia-Manero, G., Ravandi, F., Konopleva, M. Y. & Daver, N., Oct 15 2021, In: Cancer. 127, 20, p. 3761-3771 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • avelumab 100%
  • Azacitidine 76%
  • Acute Myeloid Leukemia 54%
  • Antibodies 31%
  • Bone Marrow 8%
  34 Scopus citations

• A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome

  Swaminathan, M., Kantarjian, H. M., Levis, M., Guerra, V., Borthakur, G., Alvarado, Y., DiNardo, C. D., Kadia, T., Garcia-Manero, G., Ohanian, M., Daver, N., Konopleva, M., Pemmaraju, N., Ferrajol, A., Andreeff, M., Jain, N., Estrov, Z., Jabbour, E. J., Wierda, W. G., Pierce, S., & 4 othersPinsoy, M. R., Xiao, L., Ravandi, F. & Cortes, J. E., Aug 2021, In: Haematologica. 106, 8, p. 2121-2130 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • quizartinib 100%
  • GATA2 Deficiency 72%
  • Azacitidine 69%
  • Cytarabine 59%
  • Acute Myeloid Leukemia 18%
  30 Scopus citations

• Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

  Tambaro, F. P., Singh, H., Jones, E., Rytting, M., Mahadeo, K. M., Thompson, P., Daver, N., DiNardo, C., Kadia, T., Garcia-Manero, G., Chan, T., Shah, R. R. & Wierda, W. G., Nov 2021, In: Leukemia. 35, 11, p. 3282-3286 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access
  63 Scopus citations

• CD94 expression patterns in reactive and neoplastic T-cell and NK-cell proliferations

  Fang, H., Wang, W., Kadia, T. M., El Hussein, S., Wang, S. A. & Khoury, J. D., Sep 2021, In: Leukemia Research. 108, 106614.

  Research output: Contribution to journal › Article › peer-review

  • Natural Killer Cells 100%
  • Cell Proliferation 71%
  • T-Lymphocytes 66%
  • T-Cell Lymphoma 35%
  • Neoplasms 24%
  2 Scopus citations

• Clinical and molecular characterization of myeloid sarcoma without medullary leukemia

  Abbas, H. A., Reville, P. K., Geppner, A., Rausch, C. R., Pemmaraju, N., Ohanian, M., Sasaki, K., Borthakur, G., Daver, N., DiNardo, C., Bueso-Ramos, C., Pierce, S., Jabbour, E., Garcia-Manero, G., Konopleva, M., Ravandi, F., Kantarjian, H. & Kadia, T. M., 2021, In: Leukemia and Lymphoma. 62, 14, p. 3402-3410 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Myeloid Sarcoma 100%
  • Leukemia 55%
  • Cytogenetic Analysis 15%
  • Recurrence 15%
  • Diploidy 14%
  10 Scopus citations

• Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations

  Shoukier, M., Kadia, T., Konopleva, M., Alotaibi, A. S., Alfayez, M., Loghavi, S., Patel, K. P., Kanagal-Shamanna, R., Cortes, J., Samra, B., Jabbour, E., Garcia-Manero, G., Takahashi, K., Pierce, S., Short, N. J., Yilmaz, M., Sasaki, K., Masarova, L., Pemmaraju, N., Borthakur, G., & 4 othersKantarjian, H. M., Ravandi, F., DiNardo, C. D. & Daver, N., Feb 1 2021, In: Cancer. 127, 3, p. 381-390 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Isocitrate Dehydrogenase 100%
  • Acute Myeloid Leukemia 69%
  • Protein-Tyrosine Kinases 66%
  • Mutation 41%
  • Drug Therapy 23%
  9 Scopus citations

• Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia

  Montalban-Bravo, G., Kanagal-Shamanna, R., Sasaki, K., Masarova, L., Naqvi, K., Jabbour, E., DiNardo, C. D., Takahashi, K., Konopleva, M., Pemmaraju, N., Kadia, T. M., Ravandi, F., Daver, N., Borthakur, G., Estrov, Z., Khoury, J. D., Loghavi, S., Soltysiak, K. A., Pierce, S., Bueso-Ramos, C., & 5 othersPatel, K. P., Verstovsek, S., Kantarjian, H. M., Bose, P. & Garcia-Manero, G., Sep 1 2021, In: Cancer. 127, 17, p. 3113-3124 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 100%
  • Mutation 31%
  • Survival 25%
  • Allogeneic Cells 24%
  • Stem Cell Transplantation 23%
  6 Scopus citations

• Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

  Tanaka, T., Morita, K., Loghavi, S., Wang, F., Furudate, K., Sasaki, Y., Little, L., Gumbs, C., Matthews, J., Daver, N., Pemmaraju, N., DiNardo, C. D., Sasaki, K., Yilmaz, M., Kadia, T. M., Ravandi, F., Konopleva, M. Y., Kantarjian, H. M., Champlin, R. E., Al-Atrash, G., & 4 othersGarcia-Manero, G., Wang, S. A., Futreal, P. A. & Takahashi, K., Nov 4 2021, In: Blood. 138, 18, p. 1733-1739 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hematopoiesis 100%
  • Acute Myeloid Leukemia 87%
  • Mutation 77%
  • Remission Induction 10%
  • Induction Chemotherapy 9%
  18 Scopus citations